Medicine Matters oncology

The translation of the recently presented data from the IMvigor130 trial to the clinical practice-- it's really tough to foresee at this time. Why I'm saying that? Progression-free survival was definitely statistically significant. But we need to discuss if this is clinically significant, or the robustness of the clinical significance at that time. The response rate is extremely good. The complete responses are very good, 13%. We need a longer follow-up to see what is this translation for this complete response to our patients.

The exploratory analysis of the value of PD-L1 expression in our patients, I think it is extremely relevant. There is a group of patients, probably those patients with high over expression with good performance status-- able to be selected for cisplatin-based chemotherapy-- that maybe they have a great benefit to receive atezolizumab as a single agent. Because by doing that, of course, the quality of life will be much, much better, because of the side effects profiling. But the duration of the response of these patients will be longer than one year and a half in the majority of the patients. So if we are able to select those patients in advance, probably, we will be practice changing in the field of urothelial carcinoma.